HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (12) Citing Articles via Google Scholar Google Scholar Articles by Bradwell, A. R. Search for Related Content PubMed PubMed Citation Articles by Bradwell, A. R. Related Collections Cancer Diagnostics (since 2002) Hematology

Serum Free Light Chain Measurements Move to Center Stage

Department of Immunity and Infection, The Medical School, University of Birmingham, Birmingham B15 2TT, United Kingdom, and, The Binding Site Ltd., Birmingham B14 4ZB, United Kingdom, E-mail A.R.BRADWELL@bham.ac.uk

The first 300 words of the full text of this article appear below.

For more than 150 years, the presence of Bence Jones protein [immunoglobulin free light chains (FLCs)] in the urine has been an important diagnostic marker for multiple myeloma. Indeed, it was the first cancer test, and 100 years before any others (1). Over the last few years, however, interest in FLCs has undergone a renaissance. Development of serum tests for free and free has opened the door to new applications and increased their clinical importance (2). By way of comparison, the management of diabetes mellitus was hugely improved when blood replaced urine for glucose analysis.

The report by Katzmann et al. (3) in this issue of Clinical Chemistry adds valuable confirmatory data on serum FLC testing. It is the first report of the assays being used in routine clinics with analysis of results on 1020 samples. As the authors point out, the performance of the tests has matched up to the retrospective studies that have been published previously.

From a physiologic viewpoint, blood tests for small proteins have clear advantages over urine tests. Serum FLCs are cleared rapidly through the renal glomeruli with a serum half-life of 2–6 h and are then metabolized in the proximal tubules of the nephrons. Under ordinary circumstances, little protein escapes to the urine (4), and serum FLC concentrations have to increase manyfold before the absorption mechanisms are overwhelmed. This makes urinalysis a fickle witness to changing FLC production. Conversion to a serum test provides clarity in assessing disease processes that were previously hidden from view.

Serum concentrations of FLCs are dependent on the balance between production (by plasma cells and their progenitors) and renal clearance. When there is increased polyclonal immunoglobulin production and/or renal impairment, both and FLC concentrations can increase 10- to 20-fold. However, the . . . [Full Text of this Article]

The following articles in journals at HighWire Press have cited this article:

				P. Zhou, J. Teruya-Feldstein, P. Lu, M. Fleisher, A. Olshen, and R. L Comenzo Calreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan Blood, January 15, 2008; 111(2): 549 - 557. [Abstract] [Full Text] [PDF]

				M. A. Gertz, M. Q. Lacy, A. Dispenzieri, S. R. Hayman, S. K. Kumar, N. Leung, and D. A. Gastineau Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response Haematologica, October 1, 2007; 92(10): 1415 - 1418. [Abstract] [Full Text] [PDF]

				J. A. Katzmann, A. Dispenzieri, R. A. Kyle, M. R. Snyder, M. F. Plevak, D. R. Larson, R. S. Abraham, J. A. Lust, L. J. Melton III, and S. V. Rajkumar Elimination of the Need for Urine Studies in the Screening Algorithm for Monoclonal Gammopathies by Using Serum Immunofixation and Free Light Chain Assays Mayo Clin. Proc., December 1, 2006; 81(12): 1575 - 1578. [Abstract] [Full Text] [PDF]

				J. A. Katzmann Serum Free Light Chain Specificity and Sensitivity: A Reality Check Clin. Chem., September 1, 2006; 52(9): 1638 - 1639. [Full Text] [PDF]

				P. G. Hill, J. M. Forsyth, B. Rai, and S. Mayne Serum Free Light Chains: An Alternative to the Urine Bence Jones Proteins Screening Test for Monoclonal Gammopathies Clin. Chem., September 1, 2006; 52(9): 1743 - 1748. [Abstract] [Full Text] [PDF]

				A. M. S. Muller, A. Geibel, H. P. H. Neumann, A. Kuhnemund, A. Schmitt-Graff, J. Bohm, and M. Engelhardt Primary (AL) Amyloidosis in Plasma Cell Disorders Oncologist, July 1, 2006; 11(7): 824 - 830. [Abstract] [Full Text] [PDF]